Glucagon ELISA by Ansh Labs

Although Glucagon testing has been around for decades, it has largely remained a research test because Glucagon tests specific enough to give researchers confidence in the results were laborious 2- and 3-day assays with complex sample extraction. A significant limitation to current commercially available assays is due to the lack of standardization and commutability of the methods used to measure Glucagon in peripheral circulation. Additionally, differences in the design of these methods affects not only quantitative results but also the specificity of the assays with respect to cross-reactivity with glicentin and oxyntomodulin. Such differences impact the interpretation of Glucagon measurements and potentially the validity of their research and clinical usefulness. Indeed, two studies conducted by Jens J. Holst's group in Denmark in 2014 showed that commercially available glucagon immunoassays lack the specificity, sensitivity, dynamic ranges, and precision necessary to obtaining accurate measurements of Glucagon in blood.^1,2

In consultation with several key opinion leaders, Ansh Labs has screened countless monoclonal antibodies and tested numerous assay validation protocols to identify the optimal antibody pair. We are confident that our Glucagon ELISA kit will set a new standard in glucagon testing allowing researchers to more accurately detect glucagon abnormalities in diabetes and insulin replacement therapies.

Assay Features:

• Measures Glucagon (1-29) with no detectable cross-reactivity to Glicentin, Oxyntomodulin, GLP-1, GLP-2, or GRPP
• Sensitive to 2.1 pg/mL (0.6 pmol/L); analytical measurable range of 20-313 pg/mL (6-89 pmol/L) allows for accurate quantitations on both hyperglycemiac and hypoglycemiac samples
• Simple two-step procedure with total 2.5 hour incubation at RT avoids the complex or overnight procedures inherent in current Glucagon assays
• Sample size of 50 µL, no extraction needed, no special collection tube required

References:

1. Diabetologia 2014 57:1919-1926

2. European Journal of Endocrinology 2014 170, 529-538